MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma

Statistical significance in overall survival benefit was achieved in patients aged 65 and under.

  • By

  • October 7, 2026

  • 7 min

Share

Original Source(s)

MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma

  • by

  • October 7, 2026

Related Content

Immunohistochemistry vs Molecular Breast Cancer Subtyping Among African Populations

Comment on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation”

Defensive responses to the U.S. Surgeon General’s alcohol-cancer advisory: A topic modeling analysis of TikTok comments